Video

KEYNOTE-407 Study of Frontline Pembrolizumab and Chemotherapy in Advanced NSCLC

Dr Velcheti reviews data on the chemoimmunotherapy treatment of squamous NSCLC from the KEYNOTE-407 study.

Related Videos
Nicolas Girard, MD
Hope Rugo, MD, FASCO, and Aditya Bardia, MD, MPH, FASCO
5 KOLs are featured in this series.
5 KOLs are featured in this series.
Shirish M. Gadgeel, MD
Jacob Sands, MD
Real world evidence of treatment practices and therapeutic outcomes for newly diagnosed NSCLC patients with non-classical EGFR mutations demonstrates high unmet medical need
Phase 1 trial of DLL3/CD3 IgG-Like T-Cell Engager BI 764532 in Patients with DLL3 Positive Tumors: Patients with LCNEC
Hope Rugo, MD, FASCO, and Aditya Bardia, MD, MPH, FASCO
Charu Aggarwal, MD, MPH, FASCO